Previous 10 | Next 10 |
home / stock / czo:cc / czo:cc news
EDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...
EDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic ind...
- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the Montreal Heart Institute led by MHI’s Montreal Health Innovations Coordinating Center (MHICC) EDMONTON, Alberta, Dec. 22, 2022 (GLOBE NEWSWIRE...
– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology – Q3 2022 sales of $3,845,000 vs $4,523,000 in Q3 2021 ; YTD sales increase 14% vs 2021 - $15,517,000 vs $13,633,000 ...
PGX processing unit to be installed at Agri-Food Discovery Place of University of Alberta Alginate and yeast beta glucan to be the first bio actives to be processed at this location EDMONTON, Alberta, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO;...
Findings from this collaborative project with the University of Alberta using a unique surgical methodology illustrate how PGX-processed carriers can successfully be uniformly loaded with a fat-soluble active ingredient to generate superior bioactive delivery systems Superior bi...
– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a 25% increase – YTD Sales increased 28% vs 2021 – $11,672,000 vs $9,110,000 – Income before tax of $2,177,000 in Q2 2022 vs $676,...
– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and to pave the way for Phase 1 clinical trial EDMONTON, Alberta, Aug. 11, 2022 (GLOB...
Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: ...
EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and co...
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Silvercorp Metals Inc. (SVM:CA) is expected to report $0.03 for Q4 2024 NeutriSci International Inc. (NU.H:CA) is expected to report for Q1 2024 Abcourt Mines Inc. (ABI:CA) is expected to report for Q3 2024 Corsa Coal Corp. (CSO:CA) is expected to report for Q1 2024 Urbanfund Corp...